175 related articles for article (PubMed ID: 36647944)
1. Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
Tian J; Bai T; Zhang Z; Zhai X; Wang K; Gao X; Yan B
J Cancer Res Ther; 2022 Dec; 18(7):1867-1875. PubMed ID: 36647944
[TBL] [Abstract][Full Text] [Related]
2. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
Kumar V; Mahato RI
Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence.
Czaplicka A; Lachota M; Pączek L; Zagożdżon R; Kaleta B
Cells; 2024 Jan; 13(1):. PubMed ID: 38201305
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
6. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
[TBL] [Abstract][Full Text] [Related]
8. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
10. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
Zhang J; Chen P; Miao L
Front Immunol; 2022; 13():969196. PubMed ID: 36032149
[TBL] [Abstract][Full Text] [Related]
11. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
Li H; Song W; Li Z; Zhang M
Front Immunol; 2022; 13():992232. PubMed ID: 36353643
[TBL] [Abstract][Full Text] [Related]
13. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer.
Batchu RB; Gruzdyn OV; Tavva PS; Kolli BK; Dachepalli R; Weaver DW; Gruber SA
Surgery; 2019 Oct; 166(4):503-508. PubMed ID: 31416604
[TBL] [Abstract][Full Text] [Related]
14. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.
Choi C; Finlay DK
Stem Cell Res Ther; 2021 Jun; 12(1):320. PubMed ID: 34090499
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review.
Hosseini M; Habibi Z; Hosseini N; Abdoli S; Rezaei N
Expert Opin Biol Ther; 2022 Mar; 22(3):349-366. PubMed ID: 34541989
[TBL] [Abstract][Full Text] [Related]
16. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment.
Lee YE; Ju A; Choi HW; Kim JC; Kim EE; Kim TS; Kang HJ; Kim SY; Jang JY; Ku JL; Kim SC; Jun E; Jang M
J Control Release; 2020 Oct; 326():310-323. PubMed ID: 32682905
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
18. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
